LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a clinical-stage biotechnology company that has positioned itself in the regenerative medicine space with a potentially ...
The pharmaceutical industry operates under an uncompromising mandate: zero defects. Every tablet, capsule, vial, or syringe ...
Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting ...
Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved ...
(PRESS RELEASE) BASEL, 13-Feb-2026 — / EuropaWire / — Novartis has announced final Phase III results from the ALIGN study evaluating Vanrafia (atrasentan) in adults with IgA nephropathy (IgAN), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results